Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.45 |
| ▸ | MAOA | P21397 | 10/20 | 0.45 |
| ▸ | KDM1A | O60341 | 7/20 | 0.45 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | SCN1A | P35498 | 1/20 | 0.44 |
| ▸ | SCN4A | P35499 | 1/20 | 0.44 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.44 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.44 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.44 |
| ▸ | SCN11A | Q9UI33 | 1/20 | 0.44 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphine SCHEMBL28692039 | 0.97 | MAOB (0.43) | MAOBMAOAKDM1ACACNA1FAR | |
| SCHEMBL1415063 | 0.83 | MAOB (0.39) | MAOBMAOAKDM1ACACNA1FAR | |
| SCHEMBL28829896 | 0.77 | MAOB (0.44) | MAOBMAOAKDM1A | |
| SCHEMBL5998298 | 0.75 | KDM1A (0.57) | MAOBMAOAKDM1ACACNA1FAR | |
| SCHEMBL2640739 | 0.75 | MAPT (0.59) | MAOBMAOA | |
| SCHEMBL19992872 | 0.75 | MAOB (0.64) | MAOBMAOAKDM1A | |
| SCHEMBL5076521 | 0.74 | MAOB (0.44) | MAOBMAOAKDM1ACACNA1FAR | |
| SCHEMBL11882335 | 0.74 | MAOB (0.44) | MAOBMAOAKDM1ACACNA1FAR | |
| SCHEMBL7000753 | 0.74 | MAOB (0.62) | MAOBMAOAKDM1A | |
| SCHEMBL29733492 | 0.72 | CCR2 (0.39) | MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117304234-A | Organic electroluminescent material and device | 环球展览公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-111747989-B | Organic electroluminescent material and device | 环球展览公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116891498-A | Organic electroluminescent material and device | 环球展览公司 | 2023-10-17 | — | — | CN | disclosed |
| US-20230040902-A1 | Pharmaceutical Formulation Comprising Cibenzoline or Salt Thereof | CELLTRION INC. (KR) | 2023-02-09 | — | — | US | disclosed |
| WO-2021260494-A1 | COMPOSITE MATERIAL FOR ELECTRON HOLE INJECTION LAYER, OPTICAL DEVICE, APPARATUS, MODULE, ELECTRONIC EQUIPMENT, AND LIGHTING APPARATUS | 株式会社半導体エネルギー研究所 | 2021-12-30 | — | — | WO | disclosed |
| US-20210393592-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY | CELLTRION INC. (KR) | 2021-12-23 | — | — | US | disclosed |
| CN-113201019-A | Organic electroluminescent material and device | 环球展览公司 | 2021-08-03 | — | — | CN | disclosed |
| CN-111747989-A | Organic electroluminescent material and device | 环球展览公司 | 2020-10-09 | — | — | CN | disclosed |
| WO-2020067683-A1 | NOVEL PROCESS FOR THE PREPARATION OF (+)-CIBENZOLINE SUCCINATE | CELLTRION INC. (KR) | 2020-04-02 | — | — | WO | disclosed |
| US-20150065738-A1 | PHOSPHOROUS COMPOUND AND TRANSITION METAL COMPLEX THEREOF | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-03-05 | — | — | US | disclosed |
| EP-2842959-A1 | Phosphorous compound and transition metal complex thereof | Takasago International Corporation (JP) | 2015-03-04 | — | — | EP | disclosed |
| US-5658914-A | ANTIESTROGENS, ANTITUMOR AGENTS | RESEARCH CORPORATION TECHNOLOGIES (US) | 1997-08-19 | — | — | US | disclosed |
| US-5658927-A | ANTIESTROGENS, ANTITUMOR AGENTS | RESEARCH CORPORATION TECHNOLOGIES (US) | 1997-08-19 | — | — | US | disclosed |
| US-5658951-A | ANTIESTROGENS, ANTITUMOR AGENTS | RESEARCH CORPORATION TECHNOLOGIES (US) | 1997-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065738-A1 | PHOSPHOROUS COMPOUND AND TRANSITION METAL COMPLEX THEREOF | AP2M1, AP1M1, APBA1 | MAOB 2788/4885MAOA 3593/4885KDM1A 2828/4885 |
| US-20210393592-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY | CPT1B, TNNT2, TNNC1 | MAOB 3001/4885MAOA 3931/4885KDM1A 2449/4885 |
| US-20230040902-A1 | Pharmaceutical Formulation Comprising Cibenzoline or Salt Thereof | CEL, SLC6A12, SLC6A1 | MAOB 1319/4885MAOA 1915/4885KDM1A 1712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.